Autopsy report · NCT03927443

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

“\[Sponsors decision\]”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Sun Pharmaceutical Industries Limited

Sponsor type

Industry

Conditions

Open Angle Glaucoma; Ocular Hypertension

Interventions

SDP-133; Lumigan

Participants

0

Trials that died the same way

• Single Ascending Dose Trial in Patients With Type 2 Diabetes
  “Decision by Sponsor” (76% match in meaning)
• Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program
  “Sponsor's Decision” (75% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (75% match in meaning)
• A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
  “Sponsor decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.